Managing chronic pain in elderly patients requires a CHANGE of approach

Kress, Hans-Georg

2014-06
Managing chronic pain in elderly patients requires a CHANGE of approach


To link to this article: http://dx.doi.org/10.1185/03007995.2014.887005

Accepted author version posted online: 23 Jan 2014. Published online: 06 Mar 2014.

Article views: 1205
View related articles
View Crossmark data
Citing articles: 1 View citing articles
Commentary
Managing chronic pain in elderly patients requires a CHANGE of approach

Hans-Georg Kress
Medizinische Universität/AKH Wien, Vienna, Austria

Karsten Ahlbeck
Capio S:t Görans Hospital, Stockholm, Sweden

Dominic Aldington*
Churchill Hospital, Oxford, UK

Eli Alon
Universitätsklinik Zürich, Zürich, Switzerland

Stefano Coaccioli
Santa Maria General Hospital, Terni, Italy

Flaminia Coluzzi
Department of Anesthesia, Intensive Care and Pain Therapy, Sapienza University of Rome, Italy

Frank Huygen
University Hospital, Rotterdam, The Netherlands

Wolfgang Jakusch
Schmerzambulanz, Wilhelminenspital der Stadt Wien, Austria

Eija Kalso
Helsinki University Central Hospital, Finland

Magdalena Kocot-Kępiska
Poradnia Leczenia Ból u University Hospital, Kraków, Poland

Ana Cristina Mangas
Hospital de Santo André, Leiria, Portugal

Cesar Margarit Ferri
Hospital General Universitario de Alicante, Spain

Bart Morlion
University Hospitals Leuven, Belgium

Gerhard Müller-Schwefe
Schmerz- und Palliativzentrum, Göppingen, Germany

Andrew Nicolaou
St. Georges Hospital, London, UK

Concepción Pérez Hernández
Hospital Universitario de la Princesa, Madrid, Spain

Abstract
In many countries, the number of elderly people has increased rapidly in recent years and this is expected to continue; it has been predicted that almost a quarter of the population in the European Union will be over 65 years of age in 2035. Many elderly people suffer from chronic pain but it is regularly under-treated, partly because managing these patients is often complex. This paper outlines the extent of untreated pain in this population and the consequent reduction in quality of life, before articulating the reasons why it is poorly or inaccurately diagnosed. These include the patient’s unwillingness to complain, atypical pain presentations, multiple morbidities and cognitive decline. Successful pain management depends upon accurate diagnosis, which is based upon a complete history and thorough physical examination, as well as an assessment of psychosocial functioning. Poor physician/patient communication can be improved by using standardized instruments to establish individual treatment targets and measure progress towards them. User-friendly observational instruments may be valuable for patients with dementia. In line with the widely accepted biopsychosocial model of pain, a multidisciplinary approach to pain management is recommended, with pharmacotherapy, psychological support, physical rehabilitation and interventional procedures available if required. Declining organ function and other physiological changes require lower initial doses of analgesics and less frequent dosing intervals, and the physician must be aware of all medications that the patient is taking, in order to avoid drug/drug interactions. Non-adherence to treatment is common, and various strategies can be employed to improve it, involving the elderly patient’s caregivers and family, using medication systems such as pill-boxes, or even sending text messages. In the long term, the teaching of pain medicine needs to be improved – particularly in the use of opioids – both at undergraduate level and after qualification.

Introduction
In the Western hemisphere, the elderly population has increased rapidly over past decades. For example, between 1960 and 1999 the proportion of the European population aged ≥60 years rose from 16% to 21%, while the proportion aged ≥80 years doubled or even tripled in virtually every country. This growth is expected to continue; across the 27 European Union member states, the European Commission predicts that almost a quarter of the population will be more than 65 years of age by 2035 (Table 1). In the USA, people reaching 65 years of age can expect to live another 18.6 years. Globally, approximately 10% of the world’s population is currently aged ≥65 years, but this is forecast to exceed 16% by 2050.

Many elderly people experience chronic pain; the prevalence of chronic non-cancer pain and neuropathic pain increase with age, and by the age of 70 years pain affects 79% of women and 53% of men. Managing pain in these patients is often complex, because of declining organ function, increased vulnerability to adverse side effects, the presence of comorbidities, and multiple medications. Atypical pain presentation and cognitive impairment may further complicate the picture. Today, pain is frequently under-treated in this age group, yet the...
demand for satisfactory pain management is increasing dramatically and will continue to do so.

The CHANGE PAIN initiative was established in 2009 to increase the understanding of chronic pain among healthcare professionals, to identify best practice in pain management, and to provide guidance on the treatment of patients with pain. The international CHANGE PAIN Advisory Board is composed of pain specialists from Europe and the USA, who were selected on the basis of their research activity and considerable clinical experience. At meetings on 9th and 10th December 2011, and 30th and 31st March 2012, Board members considered issues related to the incidence, diagnosis and treatment of elderly patients with pain, and discussed possible ways of improving current clinical practice.

Unmet needs

Pain is one of the most prevalent symptoms in elderly people; chronic pain is reported by approximately 60% of people aged 75 and over in the UK. However, studies have consistently shown high levels of untreated or under-treated pain in this age group. A recent systematic review of 64 studies found that the prevalence of chronic pain (i.e. of at least 3 months’ duration) in older people living in the community ranged from 25% to 76%, and in older people living in residential care ranged from 83% to 93%12. A 2010 study by Smith et al. found that unrelieved pain of at least moderate severity was experienced by a quarter (26%) of older adults (mean age 76 years) during the last 2 years of life, and this increased to nearly a half (46%) during the last month of life, regardless of the cause of death13.

Consequences of unmet needs

This under-treatment of pain has numerous consequences, many of which contribute to a reduced quality of life. Chronic pain patients exhibit significantly more mental distress than healthy controls, both when measured by self-rating and by professional assessment14. Cognitive performance may be affected by sleep disturbances and impaired emotional decision-making15,16, as a result of structural changes and behavioral deficits in cortical areas of the brain caused by chronic pain17. Many people with chronic pain report that it severely affects their ability to exercise, walk, carry out household chores and maintain an independent lifestyle18. The fact that patients with chronic pain are significantly more fatigued than healthy controls19 often leads to a decline in communal activities and social isolation. The resultant loneliness is one of the main factors leading to depression20, and these individuals experience higher levels of chronic pain than those who receive adequate social support21. In the elderly, the impact of these limitations is often greater, and may be compounded by a heavier burden being imposed upon caregivers.

Pain in the elderly: Europe today

The National Health and Wellness Survey (NHWS) is an internet-based, cross-sectional study of the healthcare attitudes, behaviors and characteristics of the
adult population in various countries, which is regularly conducted by Kantar Health of Princeton, New Jersey, USA. Core reports are produced for each country and the data obtained are analyzed according to a range of different parameters. The present analysis is based on the 2010 NHWS for the United Kingdom, France, Spain, Germany and Italy. The results are not inconsistent with previous estimates of the prevalence of pain in a much broader range of countries, but direct comparisons are difficult because different study designs, assessment methods and definitions of pain have been employed.

The prevalence of pain categorized as moderate or severe was highest in the 40–59 year age group, and mild pain was most common in the 18–39 year age group. Of the 9963 survey participants who were aged >65 years, 2083 (21%) reported experiencing pain during the last month (Table 2). The proportion of women with pain in this age group was more than twice as high as the proportion of men with pain (68%:32%). Of these older respondents with pain, the intensity was rated as severe, moderate or mild by 15%, 65% and 20%, respectively. The prevalence of depression increased progressively with the severity of pain, but was much more common among respondents below the age of 65 years than those >65 years. The majority of respondents with moderate or severe pain were receiving prescription analgesics, but the proportions were higher in the older age group: 86% and 70% for those with severe and moderate pain, respectively, compared with 81% and 56%, respectively, for the younger age group.

### Table 1. Projected population of the 27 European Union member states.

<table>
<thead>
<tr>
<th>Percentage aged 65+</th>
<th>Percentage aged 80+</th>
</tr>
</thead>
<tbody>
<tr>
<td>2008</td>
<td>2035</td>
</tr>
<tr>
<td>EU27</td>
<td>17.1</td>
</tr>
</tbody>
</table>

### Table 2. Demographic profile of survey participants by age and gender.

<table>
<thead>
<tr>
<th>Total EU (Big 5) Adults</th>
<th>Age Less than 65</th>
<th>Age 65+</th>
<th>Age 65+ (in the past month) &amp; Age 65+</th>
<th>Age 65+ (in the past month)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>51%</td>
<td>49%</td>
<td>43%</td>
<td>53%</td>
</tr>
<tr>
<td>Female</td>
<td>51%</td>
<td>49%</td>
<td>43%</td>
<td>47%</td>
</tr>
<tr>
<td>Mean Age (Years)</td>
<td>48.6</td>
<td>48.6</td>
<td>49.1</td>
<td>49.8</td>
</tr>
</tbody>
</table>

Healthy ageing

Chronic pain is a substantial burden on individuals and society, has a major impact on healthy ageing, and incurs enormous costs for healthcare systems. A systematic literature review by Kleijnen Systematic Reviews Ltd, commissioned by Grünenthal GmbH, found a clear correlation between the severity of pain and reduced quality of life (QoL). Furthermore, it revealed that the prevention and treatment of chronic pain are likely to improve QoL and could increase healthy lifespan by 2 years, which is one objective of the European Union’s Active and Healthy Ageing Partnership project. The European Federation of IASP Chapters (EFIC) recently called for European...
The challenge of diagnosis

There are various reasons why pain in elderly patients is often not diagnosed or inaccurately diagnosed. Firstly, they may fail to report their pain because they believe it is normal in old age, they are afraid it may lead to more diagnostic testing or loss of independence, or because normal in old age, they are afraid it may lead to more diagnostic testing or loss of independence, or because an accumulation of health-deteriorating factors means that a single factor (i.e. pain) gradually assumes a lower impact on self-rated health. This unwillingness to complain may be compounded by the misconception among some healthcare professionals – for which there is no scientific basis – that the elderly have a reduced perception of pain compared with younger people. Secondly, elderly patients – particularly those of most advanced age – may exhibit atypical pain presentations as a symptom of acute disease. Thirdly, multiple comorbidities are extremely common, and have a negative impact on patients' physical health and emotional, cognitive, and functional status. For the clinician, comorbidities strongly influence the diagnostic process by modifying the presentation of coexistent conditions. Fourthly, a particular problem is presented by patients whose capacity to communicate and remember has been reduced by cognitive decline, so that they are unable to provide an accurate picture of their symptoms. A further complication is that the brains of patients with Alzheimer's disease (AD), vascular dementia and frontotemporal dementia all exhibit atrophy and white matter lesions, but variations in severity and the areas affected mean that AD and frontotemporal dementia may be associated with increased levels of pain, but in vascular dementia these may be reduced. Dementia is related to a lower prevalence of reported pain and analgesic use. The reasons for this are complex, but include the use of inadequate methods to assess and document pain, a reluctance to use opioids, and physicians’ misunderstanding of the physiological and psychological components of pain.

From the clinical perspective, one factor contributing to under-diagnosis may be that the International Classification Of Diseases-10 (ICD-10) – which serves as the worldwide basis for the classification of diagnoses – does not include the diagnosis ‘chronic pain’. Furthermore, if a patient presents with pain requiring medical attention, the physician has to search multiple categories of the ICD-10 to find an adequate diagnosis, and recognition of the uniqueness of pain conditions is a precondition for adequate treatment.

Consensus point

There is a misconception among some healthcare professionals that elderly people have a reduced perception of pain and/or that pain is a normal consequence of ageing.

Improving pain diagnosis in the elderly patient

The complexity of pain assessment in elderly patients with chronic pain frequently requires a multidisciplinary approach to diagnosis. In particular, collaboration with a psychiatrist or psychologist has been recommended because of the possibility of depression, and also with a physical therapist, to help with functionality.

The cornerstone of accurate diagnosis is a thorough examination that incorporates a complete history and physical examination, focusing on the patient’s experience of pain. The location, character, frequency and intensity of the pain should be recorded, together with any exacerbating or alleviating factors and its effect on mood and sleep. Assessments should be made of any depression or cognitive impairment, the patient’s gait and balance, and his or her level of physical functioning, as demonstrated by activities of daily living (ADLs). Psychosocial functioning can be estimated from the patient’s relationship with relatives, social support groups and caregivers. The examination should be followed by any pertinent laboratory or diagnostic tests to identify the cause and subsequent pathophysiology of the pain. These investigations are important, because treatment strategies targeted at specific underlying mechanisms are likely to be most effective.

Standardized instruments

In order to achieve a common understanding of the patient’s pain experience – as well as the proposed therapy and expected outcome – effective physician/patient communication is essential. This communication is often compromised in elderly patients. Where this is the case, much valuable information can be obtained from caregivers and close relatives. Standardized instruments can improve communication and provide a greater insight into patients’ pain. Unidimensional instruments such as the Numeric Rating Scale (NRS) and Visual Analogue Scale (VAS) can be used for many elderly patients, while more information can be obtained from multidimensional instruments. Examples of these include the McGill Pain Questionnaire (MPQ), which provides a quantitative measure of subjective pain experience from an intensity
scale and three categories of word descriptors, and the CHANGE PAIN Scale, which records not only the current and target pain intensity, but also the improvement required in six key parameters that affect QoL. Patients differ enormously both in their symptoms and what they consider to be an acceptable level of pain; these instruments can help in establishing individual treatment targets and measuring progress towards them.

Patients with dementia

In patients with advanced dementia, an inability to communicate may be compounded by atypical and idiosyncratic physical and psychological behavior, which makes pain assessment extremely difficult. It should be noted, however, that stimulus detection and pain thresholds are preserved in Alzheimer’s Disease, even though anticipation and autonomic reactivity are severely affected. A number of user-friendly observational instruments have been developed to measure pain in these patients, such as the Pain Assessment in Advanced Dementia Scale (PAINAD) and the Pain Assessment Checklist for Seniors with Limited Ability to Communicate (PACSLAC). The PAINAD consists of five items (breathing, negative vocalization, facial expression, body language and consolability) that are each scored from 0 to 2, giving a range of results from 0 (no pain) to 10 (severe pain). The four subscales of the PACSLAC cover: (i) social, personality and mood indicators, (ii) facial expressions, (iii) activity and body movement, and (iv) physiological and other factors, including eating, sleep changes and vocalizations. The observer marks 60 items that indicate subtle changes in behavior as being present or absent, and the total score appears to discriminate between painful, calm and distressing events.

Consensus point

Standardized instruments can improve physician/patient communication and understanding of the patient’s pain experience.

Painvision

One innovative technology currently being developed in Belgium is Painvision. This utilizes the fact that facial expression is an important indicator of pain in patients with dementia, and that their facial responses are closely related to the intensity of noxious stimulation. During normal nursing care, facial expressions are not continuously monitored and their interpretation is not objective. Painvision is a visual system consisting of two synchronized video recording cameras and a wi-fi computer network which can continually identify discomfort in real time, and will ultimately be able to alert a caregiver via the Internet.

Improving pain management in the elderly patient

General principles

The widely accepted biopsychosocial model considers pain to be an interactive, psychophysiological behavior pattern that cannot be separated into distinct, independent psychological, social and physical components. It therefore follows that a multidisciplinary approach is recommended to investigate all possible options for optimal management, including (1) pharmacotherapy, (2) psychological support, (3) physical rehabilitation, and (4) interventional procedures. A number of studies and reviews have shown this approach to be more effective than standard, non-multidisciplinary care in reducing pain and emotional distress, and improving function. Ideally, multidisciplinary care should also involve the patient’s family and any carers, and be adapted to the patient’s individual needs. Particular caution should be exercised where the patient is being treated on an outpatient basis and lives alone. In this situation, the possible side effects of powerful analgesics — and their consequences — must be taken into consideration. The absence of a carer or suitable family member may also limit the range of potential treatments; for example, transcutaneous electrical nerve stimulation (TENS) may be excluded if there is nobody to help attach the electrodes.

Pain is not a homogeneous sensory entity. Several distinct types exist which are produced by a range of mechanisms, including nociception, peripheral sensitization, central sensitization, ectopic excitability, structural reorganization and decreased inhibition. The same painful symptom may be generated by a number of mechanisms, and a single mechanism can produce different symptoms, ranging from paresthesia to spontaneous burning pain. Not all patients with chronic pain have similar mechanisms and intensity does not reflect the neurobiological causes, only the extent to which they are activated. For pharmacological therapy, therefore, it is rational to use agents which address the likely causative mechanisms wherever possible. For example, the induction of cyclooxygenase-2 (COX-2) contributes substantially to the pain of most inflammatory conditions, so COX-2 inhibitors have a clear role here. However, these agents offer no benefit in diabetic peripheral neuropathy, where nerve injury leads to abnormal sodium channel activity and pain is mainly due to ectopic excitability.

Psychological support aims to address anxiety, stress and depression by giving patients some control over their
pain, and may include strategies such as psychotherapy, stress management, relaxation training, biofeedback and behavior modification. Counseling patients and educating them about their conditions and the anticipated outcomes can also prove valuable. The aim of physical rehabilitation is to improve physical function and help the patient to live a more independent life. It may include such elements as physiotherapy, graded exercises, postural control, pacing strategies, and functional movement to improve motor control. It is strongly recommended by the American Society of Anesthesiologists for the relief of low back pain. Interventional procedures – such as nerve blocks – can help the clinician to arrive at a precise diagnosis and may allow lower doses of medication to be prescribed.

**Declining organ function**

Organ function progressively declines with the passage of time. Between 30 years and extreme old age, there are decreases of approximately 50% or more in vital capacity, glomerular filtration rate, renal plasma flow and maximal breathing capacity (Figure 1). The function of the gastrointestinal, hemopoetic and immune systems also declines. These physiological changes may affect drug metabolism and the risk of an adverse drug reaction is greater in elderly patients. Drugs with anticholinergic activity may accelerate cognitive decline. Opioids may be associated with a higher incidence of adverse events than previously thought, including cardiovascular events, acute kidney injury and fractures, although the risk varies by opioid, adverse event and treatment duration. Prescription is further complicated by the increasing inter-individual variability in drug metabolism, drug action and adverse reactions that is a feature of advancing age, particularly when accompanied by frailty. The clinician must take this altered physiology into account when assessing potential toxicity and response to treatment.

**Consensus point**

Physiological changes must be taken into account when prescribing drugs for elderly patients.

Pharmacokinetic changes include a reduction in renal and hepatic clearance and an increase in the volume of distribution of lipid-soluble drugs, which prolong the elimination of pharmaceutical agents. Pharmacodynamic changes involve altered sensitivity to several classes of drugs, including anticoagulants, cardiovascular and psychotropic agents, which often increases their effect and the likelihood of side effects. Therefore, a lower than normal initial dose should be considered when prescribing a new medication to an elderly patient, together with less frequent dosing intervals and slow adjustment of the dosage to achieve the optimum therapeutic effect. This approach can be summed up by the adage 'start low, go slow and follow up'. A long-term view with frequent monitoring and follow up is very important, to reassess the response to therapy and to avoid either overdosing or under-treatment.

**Consensus point**

The 'start low, go slow and follow up' approach should be considered when prescribing medication to elderly patients.

The least invasive route of administration should be used; the oral route may be the most convenient and it can rapidly provide relatively steady blood concentrations, but transdermal administration may be preferred for some patients. The advantages and disadvantages of the two routes (if available) should be routinely evaluated for each patient.

The application of technology can assist in clinical decisions regarding the dosage of drugs in individual patients. For example, computerized provider order entry (CPOE) systems, where the prescriber personally enters the prescription into a computer and the prescription is then transmitted to the pharmacy, can recommend the adjustment required to allow for impaired renal function.

Some classes of drugs should be used with extreme caution in elderly patients as a result of age-related changes. Because this age group is most likely to develop delirium, it is important to avoid drugs that might increase the risk of this adverse event. A literature review on the association between medications and delirium found that benzodiazepines, opioids, dihydropyridines and antihistamines...
appear to be associated with an increased risk of delirium, but concluded that in the case of opioids caution should be tempered with the observation that untreated severe pain can itself cause delirium. In its revised guidelines for managing pain in elderly persons published in 2009, the American Geriatric Society recommends that non-steroidal anti-inflammatory drugs (NSAIDs) and COX-2 selective inhibitors ‘may be considered rarely, with extreme caution, in highly selected individuals’, citing their association with adverse events including gastrointestinal toxicity (which increases in frequency and severity with age), and interference with renal function. Furthermore, all patients taking these drugs should be routinely assessed for gastrointestinal and renal toxicity, hypertension, heart failure, and other drug-drug and disease interactions. Acetaminophen is recommended for patients with mild to moderate persistent pain, especially musculoskeletal pain, while opioid therapy should be considered for ‘all patients with moderate to severe pain, pain-related functional impairment or diminished quality of life due to pain’.

When prescribing opioids, it should be borne in mind that with all these agents – except buprenorphine – the half-life of the active drug and metabolites is increased in the elderly and in patients with renal dysfunction. It is therefore recommended that doses should be reduced, a longer time interval be used between doses, and creatinine clearance be monitored. Thus buprenorphine appears to be the first-line choice for opioid treatment in the elderly. However, the fact that it is a partial agonist at the μ-opioid receptor has implications for patients being switched to buprenorphine from a pure μ-opioid agonist, such as morphine or oxycodone. If the switch is made abruptly, the patient may experience withdrawal symptoms such as sweating, anxiety, insomnia, tachycardia, nausea, abdominal cramps and muscle pains. To prevent this, a tapering schedule should be used; the dose of the pure μ-opioid agonist is decreased by about 20–25% every day or two, while the dose of buprenorphine is simultaneously titrated upwards.

The opioid methadone requires special caution in elderly patients. Its analgesic effect lasts only 6 to 8 hours, which is much shorter than its half-life of 16 to 30 hours, so the repeated dose required for pain relief can result in accumulation of the drug in patients with reduced hepatic and renal function.

Clinicians should also be aware that opioid use is associated with an increased risk of injury and fractures, which is dose-dependent and higher for short-acting opioids than long-acting opioids, especially during the first 2 weeks of therapy. It is generally believed that the increased risk is a result of side effects such as dizziness, sedation, light-headedness and nausea leading to a greater number of falls, but some researchers have suggested that opioids might also interfere with bone formation through suppression of endogenous sex hormone production. Coanalgesics such as pregabalin, gabapentin and tricyclic antidepressants – which can themselves produce dizziness and sedation – may further compound the risk.

**Comorbidities and polypharmacy**

The presence of multiple comorbidities is particularly striking in those of very advanced age; 31% of patients aged ≥85 years have ≥4 chronic disorders. To treat these, many elderly people receive polypharmacy, with the attendant risk of drug/drug interactions that increases exponentially with the number of medications taken. It has been shown that about two-thirds of community-dwelling people aged ≥60 years take four or more medications daily, frail elderly people with multiple comorbidities take an average of nine, and elderly hospital in-patients may be prescribed as many as fourteen. The probability of interactions may be further increased by the consumption of over-the-counter (OTC) medications, which many patients perceive to be unimportant and do not disclose to their physician. One study of community-dwelling individuals aged 57 to 85 years found that 46% of those receiving at least one prescription drug were concurrently taking OTC medications, and 52% were concurrently taking dietary supplements. Thus it is important to be aware of all the medications that the patient is taking – including over-the-counter preparations – and the doses of each.

**Consensus point**

Polypharmacy is common in elderly patients, leading to an increased risk of drug/drug interactions and serious adverse events. Interactions between drugs can lead to serious adverse events or a reduction in therapeutic effect. In pharmacodynamic interactions, two or more drugs directly influence each other’s effects, whereas pharmacokinetic interactions involve the reciprocal influencing of absorption, distribution, metabolism and elimination, altering the effective concentration of the drugs at their sites of action. Common drug/drug interactions in elderly patients include (i) aspirin with ibuprofen or naproxen, increasing the cardiac risk of patients with coronary heart disease, (ii) NSAIDs with angiotensin-converting enzyme (ACE) inhibitors giving elevated serum potassium levels and possible renal failure, or with COX-2 inhibitors, increasing the risk of gastrointestinal bleeding, and (iii) combinations of drugs acting on the CNS, leading to sedation, confusion and falls.

To minimize the risk of interaction with multiple medications and serious adverse events, both the route of administration and the specific agents prescribed should...
be considered. In some circumstances, the slow increase in serum concentration offered by transdermal administration of fentanyl or buprenorphine may be advantageous; for example, the time to minimum therapeutic concentration of transdermal buprenorphine is 21 hours. This route avoids wide variations in drug concentration, which are less well tolerated by elderly patients, in line with World Health Organization guidelines. Of particular relevance to this age group, it offers ease of application and can be used when elderly patients are unable to tolerate, or unwilling to swallow, oral medication. However, care must be taken not to initiate treatment at too high a dose, as this can increase the likelihood of serious adverse events, especially in patients who are opioid-naïve.

Before initiating pharmacological treatment, a thorough assessment of all medications should be conducted and an effort made to reduce the number, if possible. When prescribing a particular class of analgesic, it may be possible to reduce the risk of subsequent drug-drug interactions by matching the specific agent to the patient's physiology and existing medication. For example, age-related decline in cytochrome P-450 function may increase the risk of toxic interactions; selective serotonin reuptake inhibitors (SSRIs) inhibit the cytochrome system and can lead to an accumulation of narcotic agents if the two drugs are administered concurrently. For example, tramadol is partly a prodrug, its analgesic action depending on both the parent drug and the M1 metabolite (O-desmethyltramadol). If demethylation of the parent drug via the cytochrome P-450 system is decreased by simultaneous administration of an SSRI, then analgesia may be reduced and the parent drug can accumulate. As the combined serotonergic activity of tramadol and the SSRI may be at least additive, the risk of a potentially fatal serotonin syndrome is increased. If an opioid is required and the current drug regime indicates a possible cytochrome P-450 interaction, then morphine, hydromorphone, oxymorphone or tapentadrol should be considered, because these are not metabolized by the cytochrome P-450 system. For tapentadrol, no clinically relevant drug-drug interactions are likely to occur through induction or inhibition of cytochrome P450 enzymes or plasma protein binding. If the glomerular filtration rate is reduced, however, then buprenorphine is an attractive option as it is excreted mainly via the liver, avoiding potentially high serum levels of opioid.

Adherence/compliance

Estimates of the extent of non-adherence in the elderly vary from 40% to 75% and there are three common forms. Some older patients take more than the prescribed dose in the mistaken belief that this will have a greater beneficial effect. Forgetting to take a dose is common, particularly when there is cognitive decline or the patient has been prescribed multiple medications. Most frequent is under-use; inappropriate drug discontinuation may occur in up to 40% of patients, particularly within the first year of a chronic care regimen.

Various strategies can be used to improve adherence in elderly patients. Communication between physician and patient should be optimized as far as possible to enable educational interventions. Where the patient is living in the community, it is important to involve any caregivers and the patient's family in the provision of practical support, providing relations within the family are good. Adherence is 1.74 times better in patients from cohesive families, but 1.53 times worse when the family is in conflict.

Consensus point

It is important to involve any caregivers and the patient's family in the provision of practical support, providing that relations within the family are good.

Emphasizing the value of the drug regimen and the benefit of adherence has been shown to be effective in improving adherence. In one study of elderly patients leaving hospital, by 12 weeks after discharge half the patients were initially taking fewer than half the prescribed tablets, and a further quarter were seriously overdosing themselves. However, a 15 minute counseling session was found to be highly effective in reducing medication errors, even in confused patients. The patient should be provided with clear instructions and the dosing regimen simplified as far as possible; for example, by using drugs with longer half-lives to reduce the number of medications and facilitate daily dosing, and by customizing the timing of doses to match the patient's lifestyle. The use of medication-taking systems (e.g. pill-boxes) to organize daily doses can reduce errors, while the attendance of community-based patients (and thus adherence) can be improved by making clinical appointments as convenient and efficient for them as possible. With the increasing integration of technology into patient care and society in general, the sending of daily text messages to remind patients to take medication has been shown to improve adherence rates in healthy young women using oral contraceptives, and this method may be transferable to elderly patients.

Elderly patients are more vulnerable to medication-related problems than younger ones, because of the dosage adjustment required by pharmacokinetic and pharmacodynamic changes, as well as the presence of comorbidities and polypharmacy. The majority of medication errors are preventable. Most are due to prescribing faults (failure in deciding the correct drug to use and how) or prescription errors (providing incorrect instructions), and
one way of reducing the number is by the application of technology. CPOE systems not only guarantee legibility and avoidance of transcription errors, they can also ensure the completeness and accuracy of prescriptions. In studies, CPOE has decreased the incidence of medication errors by $\geq 55\%$ and $95.9\%$. A similar benefit (>90% reduction in dispensing errors) has been achieved by introducing a barcode-enabled point-of-care (BPOC) system. This involves scanning a patient’s barcoded wristband and the barcode on the intended individual drug dose. Relevant patient information is then displayed on a laptop computer, which also compares the proposed dose with the patient’s drug regimen – in the event of any mismatch, an alert appears on the screen.

**Education**

For the various measures outlined above to be widely implemented, there needs to be an improvement in the teaching of pain medicine. For example, opioids remain the drugs of choice for the treatment of moderate to severe pain, but the appropriate use of these agents is often restricted by barriers such as a fear of abuse and addiction, particularly in developing countries. Misconceptions held by healthcare professionals are often a major factor in the under-use of opioids. There are widespread concerns about opioid addiction, tolerance and hyperalgesia, as well as unrealistic anxieties about precipitating adverse side effects and an unfounded assumption that long-term opioid treatment necessarily impairs patients’ quality of life. This should not be altogether surprising, as physicians responding to surveys acknowledge that they have received insufficient training in opioid pharmacology and pain management in general. The need for improved training is even more marked in the case of elderly patients, where accurate diagnosis and the satisfactory management of pain present particular challenges, and require higher levels of expertise.

Firstly, there should be a greater emphasis on pain management in the medical undergraduate curriculum. For example, the median time spent on pain management by a UK medical student is 13 hours, and in some cases as little as 6 hours. Furthermore, the subject is taught piecemeal and not as a separate module. Continuing medical education (CME), such as the PAIN EDUCATION Program offered as part of the CHANGE PAIN initiative, also has a vital role to play. Currently, six CME modules have been developed – on topics such as mechanisms of pain and the multimodal management of chronic pain – and are available online in several European languages. They are accredited by the Union Européenne des Médecins Spécialistes (UEMS) and various national bodies. A new module dealing specifically with pain in the elderly is almost complete, and will soon be available from the CHANGE PAIN website (http://www.change-pain.com).

**Conclusions**

Many elderly people have chronic pain, but studies have consistently shown high levels of untreated or under-treated pain in older people which adversely affects their quality of life. The reasons for this include the failure by patients to report pain and the misconception among some healthcare professionals that the elderly have a reduced perception of pain. Also, pain management is often challenging in these patients because of declining organ function, impaired cognition, the presence of comorbidities, increased vulnerability to side effects, and polypharmacy. In the developed world, the proportion of elderly people in the population has risen dramatically in recent years and this is expected to continue, so the need to improve pain management for this age group is becoming increasingly urgent.

A number of different approaches could prove beneficial. Standardized instruments can improve communication and help diagnose patients’ pain. A ‘start low, go slow and follow up’ approach should be considered when prescribing medications to elderly patients. The number of prescribing faults and prescription errors can be reduced by the introduction of technology, such as CPOE and BPOC systems. Non-adherence levels in elderly patients are currently high, but these could be improved by counseling on the benefits of treatment, simplifying dosage regimens, and utilizing medication-taking systems.

Finally, in order to increase awareness among the medical community of how pain management can be improved, there needs to be better teaching of pain medicine – particularly with respect to the use of opioids – both at undergraduate level and post-qualification.

**Transparency**

**Declaration of funding**

Funding for this study was provided by Grünenthal GmbH.

**Declaration of financial/other relationships**

All authors are members of the CHANGE PAIN International Advisory Board. As such, they have received honoraria for attending the meetings upon which this paper is based. In addition, H.-G.K. and G.M.-S. declare that they are chairmen of the International Advisory Board on CHANGE PAIN for Grünenthal GmbH, and receive honoraria in this context. None of the authors received honoraria for the writing of this paper.

CMRO peer reviewers may have received honoraria for their review work. The peer reviewers on this manuscript have disclosed that they have no relevant financial relationships.
Acknowledgments
Medical writing support was provided by Derrick Garwood of
Derrick Garwood Ltd, Cambridge, UK, and was funded by
Grünenthal GmbH.

References
1. Pearce D. The demographic situation in the European Union. Population
Trends 2001;104:6-11
2. European Commission. Population projections 2008–2060. Available at:
[Last accessed 15 October 2013]
Of Health And Human Services. Available at: http://www.aoa.gov/aao/aging/
April 2013]
community. Lancet 1999;354:1248-52
5. Dieterle JM, Kerklaan J, Huygen FJ, et al. Incidence rates and treatment of
neuropathic pain conditions in the general population. Pain 2008;137:681-8
depressive symptoms: a Swedish population study of 70-year-old men and
7. Rao A, Cohen HJ. Symptom management in the elderly cancer patient:
hospitalized patients. Arch Gerontol Geriatr 2010;51:273-6
10. Cassel KC. Geriatric medicine: an evidence-based approach. New York, USA:
Springer, 2003
older people. Age Ageing 2013;42:i1-7
12. Smith AK, Cenzer IS, Knight SJ, et al. The epidemiology of pain during the last
quality of life and pain in patients with chronic fibromyalgia and neuropathic
14. Apkarian AV, Sosa Y, Krauss BR, et al. Chronic pain patients are impaired on
15. Baliki MN, Chialvo DR, Geha PY, et al. Chronic pain and the emotional brain:
specific brain activity associated with spontaneous fluctuations of intensity of
chronic back pain. J Neurosci 2006;26:12165-73
16. Baliki MN, Chialvo DR, Geha PY, et al. Chronic pain and the emotional brain:
specific brain activity associated with spontaneous fluctuations of intensity of
chronic back pain. J Neurosci 2006;26:12165-73
17. Apkarian AV, Sosa Y, Sonty S, et al. Chronic back pain is associated with
decreased prefrontal and thalamic gray matter density. J Neurosci
2004;24:10410-15
or chronic neck pain fatigued? Pain Med 2004;5:187-95
21. Phillips JM, Gatchel RJ. Extraversion–introversion and chronic pain: locus of
Personality Characteristics of Patients with Pain. Washington DC: American
Psychological Association, 2000:181-202
22. Kantar Health Inc. National Health And Wellness Survey, 2010 [EU]. Princeton,
NJ, USA, 2010
pain and quality of life in Europe. Pain Pract 2013: published online 21
October 2013, doi:10.1111/pap.12125
24. AGS Panel on Persistent Pain in Older Persons. The management of persistent
25. Iyer PW. Medical-legal aspects of pain and suffering. Tucson, Arizona:
27. Morris PM, Lomranz J. Handbook of pain and aging. Basel, Switzerland:
Birkhäuser, 1997
comorbidity and self-rated pain, mood disturbance, and function in older people
30. Morrison RS, Siu AL. A comparison of pain and its treatment in advanced
dementia and cognitively intact patients with hip fracture. J Pain Symptom
Manage 2000;19:240-8
perceived daily pain in home-dwelling elderly people: a population-based
study. Age Ageing 2004;33:496-9
2003;5:55-61
34. Kaye AD, Balch A, Scott JT. Pain management in the elderly population: a
review. Ochsner J 2010;10:179-87
36. Melzack R. The McGill Pain Questionnaire: major properties and scoring
communication and pain management decisions. Curr Med Res Opin
2011;27:481-8
with different degrees of cognitive impairment and brain electrical activity
deterioration. Pain 2004;111:22-9
39. Zwakhalen SMG, Hamers JPH, Abu Saad HH, Berger MPF. Pain in elderly
people with severe dementia: a systematic review of behavioural pain assessment
40. Kunz M, Schramm S, Hemmeter U, et al. The facial expression of pain in
patients with dementia. Pain 2007;133:221-8
41. Painvision. Monitoring of discomfort in demented elderly patients based on
automatic image recognition. Available at: http://project.mobilab.be/painvi-
sion/index.html. [Last accessed 7 May 2012]
42. Turk DC, Monarch ES. Biopsychosocial perspective on chronic pain. In: Turk
chronic low back pain: a systematic review. BMJ 2001;323:1511-16
44. Scasagni L, Tomà V, Dober-Spielmann S, et al. Multidisciplinary treatment for
chronic pain: a systematic review of interventions and outcomes. Rheumatology
2008;47:670-8
45. Gatchel RJ, McGee DD, Peterson A, et al. Preliminary findings of a randomized
controlled trial of an interdisciplinary military pain program. Mil Med
2009;174:270-7
46. Rodd D, Robinson ME. The role of psychological interventions in the
management of patients with chronic pain. Psychol Res Behav Manag
2011;4:41-9
47. Mogil JS, Yu I, Busbaum AI. Pain genes?: natural variation and transgenic
48. Woolf CJ, Salter MW. Neuronal plasticity: increasing the gain in pain. Science
2000;288:1765-9
49. Julius D, Basbaum AI. Molecular mechanisms of nociception. Nature
2001;413:203-10
67. Tobias DE. Start low and go slow. Hospital Pharmacist 2003;38:504-13
77. Botteman MJ, Criel N. Inappropriate use of high doses of transdermal fentanyl at admission to a palliative care unit. Palliat Med 2011;25:111-16